Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Key amyloidosis data from ASH 2019

Morie Gertz • 7 Dec 2019
ASH 2019
Amyloidosis Rare Diseases Cyclophosphamide Dexamethasone Ixazomib

Morie Gertz, MD, MACP, Mayo Clinic College of Medicine, Rochester, MN, highlights key amyloidosis data from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. In particular, the phase III trial of ixazomib, dexamethasone, and cyclophosphamide in patients with light chain (AL) amyloidosis.

More from Morie Gertz

1:36
Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosis
Morie Gertz • 21 Nov 2022
1:33
The role of allogeneic transplantation in patients with multiple myeloma
Morie Gertz • 21 Nov 2022
1:34
The importance of identifying AH amyloidosis in patients with normal free light chain levels
Morie Gertz • 21 Nov 2022
1:37
MRD as a prognostic tool but not for clinical decision-making in multiple myeloma
Morie Gertz • 21 Nov 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals